Breaking the Silos: How the PACE-It Model Improves Outcomes in Multimorbid Patients through Integrated Social and Clinical Care
Posted inDiabetes & Endocrinology Family Medicine & Nutrition news

Breaking the Silos: How the PACE-It Model Improves Outcomes in Multimorbid Patients through Integrated Social and Clinical Care

The PACE-It pilot program demonstrates that integrating health and social care via multidisciplinary teams and technology significantly improves glycemic control, lipid management, and patient activation for individuals with complex needs, offering a scalable model for bridging systemic silos in primary care.
Bridging the Health-Social Gap: The PACE-It Model Shows Promise for Complex Multimorbidity Management
Posted inDiabetes & Endocrinology Family Medicine & Nutrition news

Bridging the Health-Social Gap: The PACE-It Model Shows Promise for Complex Multimorbidity Management

A pilot randomized controlled trial demonstrates that the PACE-It program, an integrated multidisciplinary team utilizing technology-assisted communication, significantly improves glycemic control, lipid management, and patient activation in individuals with complex diabetes and psychosocial needs.
Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Lifestyle Determinants and Metabolic Compensation in Pregnancies Complicated by Type 1 Diabetes: A Synthesis of the ENDIA Study and Recent Evidence

This review analyzes the lifestyle patterns of pregnant women with type 1 diabetes, synthesizing findings from the ENDIA study with recent evidence on nutritional adequacy, islet autoimmunity, and the molecular mechanisms of metabolic compensation.
Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study
Posted inDiabetes & Endocrinology Internal Medicine news

Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study

The Phase 3 GRACE trial demonstrates that relacorilant, a selective glucocorticoid receptor modulator, significantly maintains hypertension control in patients with Cushing’s syndrome without the safety concerns associated with non-selective antagonists, such as adrenal insufficiency or hypokalemia.
Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm
Posted inClinical Updates Diabetes & Endocrinology Neurology news

Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm

This review synthesizes findings from a national multicenter study identifying that hyperghrelinemia is a specific biomarker for Prader-Willi Syndrome, whereas other rare neurodevelopmental disorders exhibit normal ghrelin levels despite severe hyperphagia and significant caregiver burden.
Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency
Posted inClinical Updates Diabetes & Endocrinology news Pediatrics

Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency

This meta-analysis reveals that long-acting growth hormone (LAGH) is associated with a significant increase in BMI SD scores during the first year of treatment and upon switching from daily GH, suggesting a distinct metabolic profile compared to daily regimens.
OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis
Posted inDiabetes & Endocrinology Internal Medicine news

OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis

A longitudinal study of 2,260 participants confirms that oral glucose tolerance test (OGTT)-based surrogate indexes, particularly Gutt and Cederholm, are superior to fasting-only measures in predicting type 2 diabetes, providing high clinical utility for metabolic risk stratification.